Chargement en cours...
Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis
Since 1967, Rifamaycin (RIF) has been used as a first line antibiotic treatment for tuberculosis (TB), and it remains the cornerstone of current short-term TB treatment. Increased occurrence of RIF-resistant (RIF(R)) TB, ~41% of which results from the RpoB S531L mutation in RNA polymerase (RNAP), ha...
Enregistré dans:
| Publié dans: | Mol Microbiol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5344776/ https://ncbi.nlm.nih.gov/pubmed/28009073 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/mmi.13606 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|